Tempest Therapeutics, Inc. (TPST) Tops Q1 EPS by 9c

Tempest Therapeutics, Inc. (NASDAQ: TPST) reported Q1 EPS of ($0.55), $0.09 better than the analyst estimate of ($0.64).

For earnings history and earnings-related data on Tempest Therapeutics, Inc. (TPST) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22